Ani Pharmaceuticals Inc (ANIP) — SEC Filings
Ani Pharmaceuticals Inc (ANIP) — 48 SEC filings. Latest: 10-Q (May 8, 2026). Includes 32 8-K, 6 10-Q, 2 DEF 14A.
View Ani Pharmaceuticals Inc on SEC EDGAR
Overview
Ani Pharmaceuticals Inc (ANIP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 10, 2025: ANI Pharmaceuticals, Inc. filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits. The filing does not contain specific financial figures or operational details in the provided text, but indica
Sentiment Summary
Across 48 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 43 neutral, 1 mixed. The dominant filing sentiment for Ani Pharmaceuticals Inc is neutral.
Filing Type Overview
Ani Pharmaceuticals Inc (ANIP) has filed 6 10-Q, 32 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 2 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (48)
Risk Profile
Risk Assessment: Of ANIP's 41 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $636.3M |
| Net Income | $50.8M |
| Cash Position | $262.6M |
| Total Assets | $1,408.15M |
| Total Debt | $312.9M |
Key Executives
- Michael L. Miller
- Nikhil Lalwani
- Robert E. Brown, Jr.
- Robert A. Graham
- December 29, 2023
- February 13, 2024
- David Rosen
Industry Context
ANI Pharmaceuticals operates in the pharmaceutical sector, specifically focusing on branded and generic prescription drugs. The industry is characterized by intense competition, regulatory oversight, and evolving pricing pressures. Companies often pursue growth through product development, strategic acquisitions, and efficient supply chain management.
Top Tags
financial-reporting (11) · 8-K (9) · pharmaceuticals (7) · acquisition (6) · sec-filing (4) · regulation-fd (4) · Pharmaceuticals (3) · 10-Q (3) · drug-rights (3) · ANI Pharmaceuticals (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Revenues | $636.3M | Increased 50.1% for the nine months ended September 30, 2025, from $423.8 million in 2024. |
| Net Income | $50.8M | Swung from a net loss of $8.2 million in 2024 to a profit for the nine months ended September 30, 2025. |
| Cash and cash equivalents | $262.6M | Increased from $144.9 million at December 31, 2024, demonstrating strong liquidity. |
| Operating income | $76.3M | Increased significantly from $5.0 million in 2024 for the nine months ended September 30, 2025. |
| Contingent consideration fair value adjustment | $(25.3)M | A favorable adjustment for the nine months ended September 30, 2025, compared to $1.3 million in 2024. |
| Interest expense, net | $15.6M | Increased from $11.6 million in 2024 for the nine months ended September 30, 2025. |
| Accrued government rebates | $37.0M | Increased from $18.7 million at December 31, 2024. |
| Inventories | $146.5M | Increased from $136.8 million at December 31, 2024. |
| Net Loss (Q2 2025) | -$1.5M | Significant decline from $1.2M net income in Q2 2024. |
| Net Loss (YTD June 2025) | -$2.8M | Reversal from $2.5M net income in YTD June 2024. |
| Retained Earnings (June 30, 2025) | $7.7M | Decreased from $10.5M at December 31, 2024, indicating reduced accumulated profits. |
| Accumulated Other Comprehensive Income (June 30, 2025) | $0.5M | Decreased from $0.8M at December 31, 2024. |
| SEC File Number | 001-31812 | Identifier for ANI Pharmaceuticals, Inc. |
| IRS Employer Identification No. | 58-2301143 | Tax identification for ANI Pharmaceuticals, Inc. |
| I.R.S. Employer Identification No. | 58-2301143 | Company identification number |
Forward-Looking Statements
- {"claim":"ANI Pharmaceuticals Inc. will likely see continued institutional interest due to Vanguard's significant stake.","entity":"ANI Pharmaceuticals Inc.","targetDate":"12-29-2024","confidence":"medium"}
- {"claim":"Other institutional investors may re-evaluate their positions in ANI Pharmaceuticals, Inc. following Rubric Capital Management LP's exit.","entity":"ANI Pharmaceuticals, Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"ANI Pharmaceuticals, Inc. will release its full financial results for the period covered by the 'Results of Operations and Financial Condition' item within the next few days.","entity":"ANI PHARMACEUTICALS, INC.","targetDate":"2024-02-15","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ani Pharmaceuticals Inc (ANIP)?
Ani Pharmaceuticals Inc has 48 recent SEC filings from Jan 2024 to May 2026, including 32 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ANIP filings?
Across 48 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 43 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Ani Pharmaceuticals Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ani Pharmaceuticals Inc (ANIP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ani Pharmaceuticals Inc?
Key financial highlights from Ani Pharmaceuticals Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ANIP?
The investment thesis for ANIP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ani Pharmaceuticals Inc?
Key executives identified across Ani Pharmaceuticals Inc's filings include Michael L. Miller, Nikhil Lalwani, Robert E. Brown, Jr., Robert A. Graham, December 29, 2023 and 2 others.
What are the main risk factors for Ani Pharmaceuticals Inc stock?
Of ANIP's 41 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 24 low-risk.
What are recent predictions and forward guidance from Ani Pharmaceuticals Inc?
Recent forward-looking statements from Ani Pharmaceuticals Inc include guidance on {"claim":"ANI Pharmaceuticals Inc. will likely see continued institutional interest due to Vanguard's significant stake. and 2 other predictions.